

Chromoblastomycosis: An Update On Pathogenesis, Clinical Features, And Diagnosis

Ganesh Sonawane^{1*}, Kajal Pansare¹, Chandrashekhar Patil¹, Sunil Mahajan¹, Deepak Sonawane¹

¹Divine College of Pharmacy, Satana Dist. Nashik-423301, Maharashtra (India)

*Corresponding author: gbsonawane8@gmail.com

Received on: 01/12/2024 Accepted on: 20/12/2024 Published on: 26/03/2025

ABSTRACT

Chromoblastomycosis is a chronic, subcutaneous fungal infection primarily caused by dematiaceous fungi, such as *Fonsecaea pedrosoi* and *Cladophialophora carrionii*. It presents as verrucous skin lesions and predominantly affects individuals in tropical and subtropical regions, particularly farmers and laborers. The disease progresses slowly, often leading to significant morbidity due to its complications, including secondary infections and potential squamous cell carcinoma. Diagnosis is challenging and typically involves direct microscopy, histopathology, culture techniques, and emerging molecular methods. Recent advancements in diagnostic tools, such as next-generation sequencing and MALDI-TOF MS, offer promising avenues for improving early detection and species identification. Despite these advances, gaps remain in our understanding of the fungal pathogenesis, immune response, and host-pathogen interaction. This review discusses the etiology, pathogenesis, clinical features, diagnostic methods, and recent advances in the management of chromoblastomycosis. The need for further research, novel diagnostic tools, and global surveillance systems to enhance patient outcomes is emphasized.

KEYWORDS: Chromoblastomycosis, *dematiaceous fungi*, *Fonsecaea pedrosoi*, *Cladophialophora carrionii*, skin lesions, fungal infections

INTRODUCTION

Chromoblastomycosis (CBM) is a chronic, progressive, granulomatous fungal infection of the skin and subcutaneous tissues caused by melanized (dematiaceous) fungi. It occurs primarily in tropical and subtropical regions, often affecting individuals with frequent traumatic exposure to soil and plant matter. The disease is characterized by slow-growing verrucous, nodular, or plaque-like lesions that can lead to significant morbidity, including secondary infections, lymphedema, and, in rare cases, malignant transformation. CBM is considered a neglected tropical disease (NTD) due to its association with poverty, lack of awareness, and limited healthcare access in endemic regions. (1)

The first detailed case of Chromoblastomycosis was described by Maximilian Rudolf in 1914, who identified *Fonsecaea pedrosoi* as the causative agent in Brazil. Initially referred to as “verrucous dermatitis,” the disease was further characterized in subsequent years through clinical and histopathological studies. The term Chromoblastomycosis was later coined to describe the presence of characteristic muriform cells or “sclerotic bodies” seen in infected tissue, which remain the hallmark of the disease. Since then, multiple cases have been

reported worldwide, particularly in tropical regions of Africa, Latin America, and Asia.(2-3)

Despite being identified over a century ago, Chromoblastomycosis remains a significant public health issue due to its chronicity, diagnostic challenges, and treatment difficulties. Advances in understanding the pathogenesis of CBM, including the role of fungal virulence factors (e.g., melanin) and host immune responses, have provided new insights into disease progression and persistence. Moreover, improved diagnostic techniques, such as molecular tools (e.g., PCR, sequencing), have enabled earlier and more precise identification of causative agents, which is critical for timely intervention. However, challenges persist, especially in low-resource settings where clinical and laboratory facilities are limited. This review aims to consolidate recent updates on pathogenesis, clinical features, and diagnostic advances to bridge knowledge gaps and improve disease management strategies. (4-6)

The primary objective of this review is to provide an updated overview of the pathogenesis of Chromoblastomycosis, emphasizing the mechanisms of fungal infection and host-pathogen interactions that contribute to the disease's chronicity and progression. Additionally, this review aims to discuss the

clinical features and variations of Chromoblastomycosis, focusing on the types of lesions, their progression over time, and associated complications such as secondary infections and lymphedema.

This review will address gaps in current knowledge, emphasize challenges faced in clinical and laboratory settings, and explore opportunities for improving early detection and management of Chromoblastomycosis. By consolidating these updates, we aim to provide a comprehensive resource for clinicians, researchers, and public health practitioners working in endemic areas.

ETIOLOGY AND CAUSATIVE AGENTS

Chromoblastomycosis is caused by a group of melanized (dematiaceous) fungi that are naturally present in the environment, particularly in soil, plant debris, and decaying vegetation. These fungi are opportunistic pathogens, gaining access to the skin and subcutaneous tissues through traumatic inoculation, such as injury caused by thorns, splinters, or other sharp objects. The most common causative species include *Fonsecaea pedrosoi*, *Cladophialophora carrionii*, *Phialophora verrucosa*, *Rhinocladiella aquaspersa*, and *Fonsecaea compacta*. Among these, *Fonsecaea pedrosoi* and *Cladophialophora carrionii* are the leading agents worldwide, responsible for the majority of reported cases.(7)

Characteristics of Causative Fungi

Dematiaceous fungi possess a distinct dark pigmentation due to the presence of melanin in their cell walls, which serves as a virulence factor, protecting the fungi from host immune responses and environmental stress.

Morphology:

***Fonsecaea pedrosoi*:** This is the most prevalent etiological agent, particularly in humid tropical regions. Microscopically, it produces brown, septate hyphae and conidia with a “branching” appearance, resembling a tree-like structure.

***Cladophialophora carrionii*:** This species is more common in arid regions. It produces elongated, branched conidiophores that give rise to chains of smooth-walled conidia.

***Phialophora verrucosa*:** Characterized by flask-shaped phialides that produce oval or spherical conidia at their tips, giving it a unique “vase-like” appearance under microscopy.

***Rhinocladiella aquaspersa*:** It produces compact, brown, and cylindrical conidiophores, resembling small warty structures.

Culture Features:

Dematiaceous fungi grow slowly in laboratory culture, typically on Sabouraud dextrose agar (SDA) or potato dextrose agar (PDA). Colonies appear dark, ranging from olive-green to black, with a velvety or woolly texture. Identification of species can be confirmed using microscopy, pigment production, and molecular techniques. For instance, *Fonsecaea pedrosoi* produces black colonies with short, branching conidiophores under laboratory conditions.(8)

Virulence Factors:

The virulence of these fungi is primarily attributed to:

Melanin Production: Melanin provides protection against oxidative stress, phagocytosis, and antifungal agents, enabling fungal persistence within host tissues.

Sclerotic Bodies: The hallmark of Chromoblastomycosis is the presence of muriform (sclerotic) bodies in infected tissue, which are thick-walled, brownish fungal elements that resist host immune responses and antifungal treatment.

Adhesion Factors: The ability of these fungi to adhere to and invade host tissues is mediated by surface proteins, promoting fungal colonization and chronic infection.

Geographical Distribution of the Key Fungal Species

The distribution of Chromoblastomycosis and its causative agents (Table 1) is closely linked to environmental conditions, particularly in tropical and subtropical climates:

***Fonsecaea pedrosoi*:** This species is predominant in humid tropical regions of South America (e.g., Brazil, Venezuela) and Southeast Asia (e.g., India, China, Thailand).

***Cladophialophora carrionii*:** It thrives in semi-arid regions, such as Northern Australia, parts of Africa (e.g., Madagascar), and the Middle East.

***Phialophora verrucosa* and *Rhinocladiella aquaspersa*:** These species have a wider, albeit less frequent distribution, being reported in North America, Japan, and

parts of Europe.(9)

Several ecological and occupational factors influence the prevalence of these fungi, including agricultural work, exposure to contaminated soil, and traumatic injury from vegetation. Additionally, the environmental resilience of dematiaceous fungi allows them to persist for prolonged periods, making endemic regions more susceptible to outbreaks.(8)

EPIDEMIOLOGY

Global and Regional Distribution of Chromoblastomycosis

Chromoblastomycosis is a chronic, neglected tropical disease with a global distribution predominantly in tropical and subtropical regions. It has been reported across continents, including South America, Africa, Asia, and Oceania, but is rare in Europe and North America. The disease burden is disproportionately high in developing countries, where access to healthcare and diagnostic facilities remains limited. The highest prevalence of Chromoblastomycosis is observed in Brazil,

Madagascar, Mexico, Venezuela, China, and India. In Brazil, the states of Pará and Maranhão are particularly endemic, accounting for numerous reported cases. Similarly, Madagascar is a significant hotspot in Africa, with a high burden of cases reported from rural areas.(10)

In Asia, countries such as India, China, Thailand, and Japan show considerable disease prevalence. The disease has also been documented in semi-arid regions of Australia and the Middle East, where specific causative fungi such as *Cladophialophora carrionii* thrive. In contrast, sporadic cases have been reported in non-endemic regions like Europe and North America, often linked to immigrants or travelers from endemic areas.

High-Prevalence Areas

The prevalence of Chromoblastomycosis is strongly associated with tropical and subtropical climates. Regions with high humidity, warm temperatures, and abundant vegetation favor the survival and proliferation of dematiaceous fungi in soil and plant debris. Endemic areas are often rural or agricultural, where occupational exposure to soil and organic materials is common.

South America: Brazil, Venezuela, and Colombia.

Africa: Madagascar, South Africa, and Sudan.

Asia: India (Tamil Nadu, Kerala), China (Guangxi), Thailand, and Japan.

Oceania: Northern Australia.

These regions share climatic and environmental conditions that promote fungal colonization and increase human exposure through traumatic inoculation.(11)




Figure 1: Causative Agents of Chromo-blastomycosis

Table 1: Key Causative Agents of Chromoblastomycosis and Their Characteristics

Causative Agent	Morphology	Culture Features	Geographical Distribution	Virulence Factors
<i>Fonsecaea pedrosoi</i>	Muriform cells, septate hyphae	Slow-growing, velvety brown to black colonies	Tropical and subtropical regions	Melanin production, enzymatic activity
<i>Cladophialophora carrionii</i>	Septate hyphae, elongated conidia	Black colonies with distinct radial grooves	Arid and semi-arid regions (e.g., Venezuela, Australia)	Resistance to oxidative stress
<i>Phialophora verrucosa</i>	Flask-shaped phialides, spherical conidia	Dark, compact colonies with short chains of conidia	Worldwide, particularly in tropical areas	Protease production, immune evasion mechanisms
<i>Rhinocladiella aquaspersa</i>	Conidia borne in clusters at hyphal tips	Gray to black colonies	Predominantly in tropical areas	Adaptation to human tissue
<i>Exophiala dermatitidis</i>	Yeast-like cells, septate hyphae	Slimy, black colonies	Global, often in hot and humid regions	Thermotolerance, melanin production

Demographic Trends

Chromoblastomycosis exhibits clear demographic trends concerning age, gender, and occupational risk.

Age and Gender: The disease predominantly affects middle-aged men (30–60 years). The male-to-female ratio is approximately 5:1, attributed to differences in occupational exposure and outdoor activities. However, sporadic cases in women and children have also been reported, particularly in endemic households where domestic tasks include exposure to contaminated soil.

Occupational Risk Groups: The majority of cases occur in individuals with occupations that involve frequent skin trauma and exposure to contaminated soil or vegetation. High-risk groups include:

Farmers: Agricultural workers are the most affected due to constant exposure to soil and sharp vegetation.

Laborers: Construction and forestry workers are also at significant risk due to occupational injuries.

Barefoot Workers: In rural areas, individuals who work barefoot face increased exposure to traumatic inoculation.

Socioeconomic Factors: The disease is more common in low-income communities where protective measures (e.g., footwear and gloves) are often unavailable, and access to healthcare is limited, resulting in delayed diagnosis and treatment.

Environmental Factors Influencing Infection Rates

Environmental factors play a critical role in the incidence of Chromoblastomycosis, particularly in endemic regions.

Climatic Conditions: Warm, humid climates promote fungal growth and persistence in soil and decaying organic matter. Fungi like *Fonsecaea pedrosoi* and *Cladophialophora carrionii* thrive under such conditions.

Soil and Vegetation: Contaminated soil and plant debris act as primary reservoirs of dematiaceous fungi. Agricultural and forested environments are hotspots for fungal proliferation and subsequent human exposure.

Occupational Exposure: Activities that involve contact with contaminated soil, such as farming, forestry, and gardening, are significant risk factors. The absence of personal protective equipment (PPE) exacerbates in-

fection rates.

Injuries and Trauma: Minor skin trauma, such as cuts, punctures, or abrasions caused by thorns, splinters, and agricultural tools, serves as the entry point for fungal inoculation.

Seasonal Variation: In some regions, seasonal patterns have been observed, with increased cases during rainy seasons when soil humidity and outdoor activities are at their peak.(12)

PATHOGENESIS

Mode of Entry

The pathogenesis of Chromoblastomycosis begins with the traumatic implantation of fungal spores or conidia into the skin or subcutaneous tissues. This usually occurs through skin injuries, such as cuts, abrasions, or puncture wounds caused by thorns, splinters, or contaminated agricultural tools. Occupational exposure, particularly in individuals engaged in farming, forestry, and other manual labor activities, significantly increases the risk of fungal inoculation. Once the fungal spores enter the skin, they establish localized infection, leading to chronic granulomatous inflammation.(13)

Fungal Adaptation

Following entry, the causative fungi (e.g., *Fonsecaea pedrosoi*, *Cladophialophora carrionii*) adapt to the hostile human tissue environment by transforming into muriform cells (sclerotic bodies), which are thick-walled, brown, septate cells. These muriform cells are highly resistant to host immune defenses and antifungal therapy, contributing to the persistence of infection. The melanin pigment in fungal cell walls provides additional protection by scavenging free radicals, reducing oxidative stress, and enhancing fungal survival.

The production of muriform cells is a key histological hallmark of Chromoblastomycosis and is considered a survival mechanism. These cells are rarely phagocytosed, allowing the fungi to evade host immune responses and persist in tissues for prolonged periods.

Immune Response

The immune response to Chromoblastomycosis involves a

complex interplay between the host and the pathogen, including both innate and adaptive immune systems.

Host-Pathogen Interaction: The initial immune response is triggered by fungal pathogen-associated molecular patterns (PAMPs), such as melanin and β -glucans, which are recognized by host pattern recognition receptors (PRRs) like dectin-1 and Toll-like receptors (TLRs). This interaction activates innate immune cells such as macrophages and neutrophils, which attempt to phagocytose and destroy the fungal cells. However, the muriform cells resist phagocytosis, limiting the effectiveness of this response.

Role of the Innate and Adaptive Immune Systems

Innate Immunity: Macrophages and neutrophils play a key role in the early stages of infection by releasing pro-inflammatory cytokines (e.g., $\text{TNF-}\alpha$, $\text{IL-1}\beta$) and reactive oxygen species (ROS). However, their ability to eliminate the fungi is hampered by the melanin-rich cell walls of muriform cells.

Adaptive Immunity: T-helper (Th) cells, particularly Th1 and Th17 subsets, mediate the adaptive immune response. The Th1 response leads to the production of $\text{IFN-}\gamma$, which activates macrophages and enhances fungal clearance. Conversely, the Th2 response is associated with chronic inflammation and granuloma formation.

Th17 Cells: IL-17 , produced by Th17 cells, is critical for neutrophil recruitment and fungal clearance, but its overproduction may exacerbate tissue damage.

Mechanisms of Immune Evasion by Fungi

The causative fungi employ several strategies to evade the host immune response:

Melanin Production: Melanin in fungal cell walls acts as a physical barrier against phagocytosis, oxidative stress, and antifungal agents.

Muriform Cell Formation: These cells are resistant to enzymatic degradation and phagocytosis, enabling fungal persistence.

Suppression of Host Immunity: Some fungal species inhibit immune cell activation and cytokine production, thereby dampening the immune response.⁽¹⁴⁾

Pathological Changes in the Skin and Underlying Tissues

The chronic nature of Chromoblastomycosis results in progressive pathological changes, primarily affecting the skin and underlying tissues.

Granulomatous Inflammation: The hallmark pathological feature is the formation of granulomas, which are aggregates of macrophages, epithelioid cells, and giant cells surrounding fungal muriform cells.

Epidermal Hyperplasia: The overlying epidermis often shows pseudoepitheliomatous hyperplasia due to chronic irritation and inflammation.

Fibrosis and Necrosis: Chronic inflammation leads to significant fibrosis of the dermis and subcutaneous tissues, as well as focal areas of necrosis. This contributes to the development of verrucous (warty) and nodular lesions.

Lymphatic Obstruction: Advanced cases may exhibit lymphatic obstruction, resulting in lymphedema and elephantiasis-like changes.

Role of Melanin and Fungal Virulence Factors in Disease Progression

Melanin plays a pivotal role in the virulence of Chromoblastomycosis-causing fungi. It provides several survival advantages that contribute to disease progression:

Protection from Oxidative Damage: Melanin scavenges reactive oxygen and nitrogen species produced by host immune cells, protecting fungal cells from oxidative stress.

Inhibition of Phagocytosis: Melanin-rich muriform cells resist phagocytosis by macrophages and neutrophils, allowing fungal persistence.

Resistance to Antifungal Therapy: Melanin in the fungal cell wall reduces the efficacy of antifungal drugs, complicating treatment.

In addition to melanin, other fungal virulence factors, such as proteolytic enzymes and adhesins, play a role in tissue invasion and colonization. Proteases degrade host tissue components, facilitating fungal dissemination, while adhesins mediate fungal attachment to host cells.⁽¹⁵⁾

CLINICAL FEATURES

Chromoblastomycosis is a chronic, progressive fungal infection that primarily affects the skin and subcutaneous tissues. The clinical presentation is highly variable and depends on the duration of infection, the immune status of the host, and the geographic region in which the disease occurs.

Initial Presentation

The disease typically begins with papules, nodules, or plaques that appear on the skin after fungal inoculation, usually through trauma such as cuts or abrasions. The initial lesions are small and often asymptomatic, but they may be pruritic or tender. These early lesions are often mistaken for other skin conditions, which can delay diagnosis. As the infection progresses, these initial lesions develop into more distinctive forms, making clinical diagnosis more evident.⁽¹⁶⁾

Progression of Lesions

If left untreated, the disease progresses over months or years, leading to the development of verrucous or cauliflower-like lesions. These lesions are typically hyperkeratotic, raised, and often have a characteristic warty appearance with irregular surfaces. As the infection progresses, the skin becomes thickened, and the lesions can ulcerate. In advanced cases, the lesions may become tumoral or fibrotic. The lesion surfaces are often crusted or scabbed, and the underlying tissue may exhibit signs of chronic inflammation, such as fistulization or sinus formation.⁽¹⁴⁾

Classification of Lesions

Chromoblastomycosis lesions can be classified into various types (Table 2), based on their clinical appearance and progression:

Nodular Type: Characterized by the formation of firm, well-defined nodules. These may ulcerate and form crusts or discharge, but they typically remain localized.

Tumoral Type: Involves larger, more elevated, fleshy masses that may spread to surrounding tissues. Tumoral lesions are often mistaken for neoplastic growths due to their large size.

Verrucous Type: The most common presentation, marked by warty, cauliflower-like lesions with a dry, scaly surface. These lesions can be painful and may lead to functional impairments due to their size and location.

Cicatricial Type: This type occurs when lesions heal and scar tissue replaces the affected skin. The scarring may be significant, leading to contractures and permanent deformities in severe cases.

Common Sites of Infection

Chromoblastomycosis most commonly affects the lower limbs, with feet and legs being the primary sites of infection due to frequent exposure to soil and vegetation in individuals working in agriculture or outdoor environments. The upper limbs are the second most common site, especially in individuals with frequent exposure to wood or plant materials. The infection rarely affects other body parts, but it can also involve the face, head, trunk, and genital areas in less common cases. In advanced stages, the infection may spread to deeper tissues, including the bones and internal organs, though such occurrences

Table 2. Clinical Classification of Chromoblastomycosis Lesions

Type of Lesion	Description	Appearance	Clinical Relevance
Nodular Lesions	Small, firm, and raised nodules, often the initial presentation	Smooth or verrucous surface	Represents the early stage of infection; may progress if untreated
Tumoral Lesions	Large, cauliflower-like masses formed by coalescing nodules	Verrucous, lobulated, and thick	Associated with advanced disease and significant tissue damage
Verrucous Lesions	Rough, warty plaques that may ulcerate	Irregular, dark, and hyperkeratotic	Commonly seen in tropical regions; prone to secondary infections
Cicatricial Lesions	Flat, atrophic areas of healed lesions	Depigmented, scar-like appearance	Indicates partial resolution or regression of active disease
Plaque Lesions	Flat, slightly raised patches with a scaly or crusty surface	Red to brown, occasionally with edema	Intermediate stage between nodular and tumoral forms

are extremely rare.

Complications

The complications associated with Chromoblastomycosis can be both local and systemic.

Secondary Infections: The chronic nature of the infection makes the lesions prone to secondary bacterial infections. These can exacerbate the symptoms and make treatment more challenging.

Lymphedema: Chronic infection and tissue damage often lead to lymphedema, especially in the lower limbs, due to lymphatic obstruction or fibrosis of the affected tissues. This can cause significant swelling and functional impairment, resembling the appearance of elephantiasis in advanced cases.

Squamous Cell Carcinoma: Although rare, squamous cell carcinoma (SCC) can develop in long-standing, untreated lesions. Chronic inflammation and cell turnover in the affected tissues may increase the risk of malignant transformation, particularly in individuals with weakened immune systems or those who have had the disease for many years.

Clinical Variations Based on Geographic Region and Individual Immunity

The clinical presentation of Chromoblastomycosis can vary significantly based on geographic location and the host's immune response.

Geographic Variations: In tropical and subtropical regions, where the disease is most common, lesions tend to be more extensive and present at earlier stages. In temperate regions, the disease may develop more slowly, and cases are often associated with fewer lesions or a more localized presentation.

Immune Status: Immunocompetent individuals typically develop localized infections with limited systemic involvement. However, immunocompromised individuals (such as those with HIV/AIDS, diabetes, or malignancies) may experience more aggressive forms of the disease, with widespread lesions and potential involvement of internal organs. The immune response also plays a role in the severity and duration of the

disease. For instance, individuals with strong cell-mediated immunity tend to present with less severe disease and have a better prognosis.(17)

DIFFERENTIAL DIAGNOSIS

Chromoblastomycosis shares clinical features with several other cutaneous diseases, which can complicate its diagnosis. Accurate diagnosis is critical, as effective treatment depends on identifying the specific cause of the skin lesions. The following conditions should be considered in the differential diagnosis of Chromoblastomycosis:

Sporotrichosis

Sporotrichosis is a fungal infection caused by *Sporothrix schenckii*, typically transmitted through the traumatic implantation of spores via plant material or other environmental sources. Like Chromoblastomycosis, it presents with nodular or ulcerative lesions on the skin, commonly on the limbs. However, sporotrichosis tends to form nodular lymphangitis, with multiple, well-defined nodules that follow the course of lymphatic channels, distinguishing it from the verrucous lesions often seen in Chromoblastomycosis. Laboratory differentiating points include the growth of *S. schenckii* in culture, which appears as cigar-shaped yeast at 37°C and a mould at 25°C, contrasting with the dematiaceous fungi seen in Chromoblastomycosis, which are typically darkly pigmented on culture.(14)

Mycetoma

Mycetoma is a chronic, subcutaneous infection typically caused by either fungal (e.g., *Madurella*, *Exophiala*) or bacterial agents. The disease is characterized by swelling, abscesses, and sinus tracts that often discharge pus containing grains. While Chromoblastomycosis also presents with nodules and verrucous lesions, mycetoma's distinguishing features include the presence of grains in the discharge, and it often involves deeper tissue layers and bone, whereas Chromoblastomycosis typically affects only the skin and subcutaneous tissues. Histological examination reveals granules in mycetoma that are absent in Chromoblastomycosis, where the hallmark is the presence of muriform (sclerotic) cells.(1)

Cutaneous Tuberculosis

Cutaneous tuberculosis (TB) is caused by *Mycobacterium tuberculosis* and presents with ulcerating lesions, scarring, and sometimes tuberculomas. Unlike Chromoblastomycosis, cutaneous TB often follows systemic spread from pulmonary infection and tends to affect immunocompromised individuals or those with poor nutritional status. The lesions of cutaneous TB typically start as papules or plaques and can ulcerate, but the histological appearance of cutaneous TB reveals granulomatous inflammation and acid-fast bacilli on staining, distinguishing it from the fungal cells seen in Chromoblastomycosis. Culture and molecular diagnostics (such as PCR for *M. tuberculosis*) help confirm the diagnosis.

Leprosy

Leprosy, caused by *Mycobacterium leprae*, presents with hypoesthetic lesions that may appear as plaques or nodules. Unlike Chromoblastomycosis, leprosy is often associated with nerve involvement, leading to sensory loss and peripheral nerve damage. The lesions in leprosy are usually painless, and the absence of sclerotic cells differentiates it from Chromoblastomycosis. Skin biopsy will show granulomatous inflammation with acid-fast bacilli in leprosy, while Chromoblastomycosis will show darkly pigmented fungal cells. A skin smear or PCR testing can help confirm the diagnosis of leprosy.

Verrucous Carcinoma

Verrucous carcinoma is a well-differentiated form of squamous cell carcinoma that presents with verrucous lesions, which can resemble the warty lesions of Chromoblastomycosis. However, verrucous carcinoma usually shows a slow, indolent growth pattern without the underlying inflammation and pigmented fungal cells found in Chromoblastomycosis. Histopathological examination will reveal keratinizing squamous cells and a lack of fungal structures, which can be distinguished from the fungal sclerotic cells and pigmentation characteristic of Chromoblastomycosis.⁽¹⁸⁾

Key Clinical and Laboratory Differentiating Points

Sporotrichosis: Nodular lymphangitis, cigar-shaped yeast in tissue culture, absence of fungal pigmentation.

Mycetoma: Presence of grains in exudate, deeper tissue and bone involvement, granule formation in histology.

Cutaneous Tuberculosis: Granulomatous inflammation, acid-fast bacilli on staining, no fungal sclerotic cells.

Leprosy: Hypoesthetic lesions, nerve involvement, absence of fungal cells, acid-fast bacilli present in biopsy.

Verrucous Carcinoma: Slow-growing, keratinizing squamous cells, absence of fungal pigmentation or sclerotic cells.

DIAGNOSIS

The diagnosis of Chromoblastomycosis involves a combination of clinical evaluation, laboratory techniques, and sometimes advanced molecular methods. Given the chronic nature of the disease and its presentation with cutaneous lesions, accurate diagnosis is critical for appropriate management and treatment.

Clinical Diagnosis

The initial clinical diagnosis is based on the recognition of characteristic skin lesions. The disease typically presents as papules, nodules, or plaques, which gradually progress to verrucous, cauliflower-like lesions. In advanced stages, ulceration and scarring may occur, leading to deformity. The lesions are most commonly found on the lower limbs, although they can occasionally involve the upper limbs and other areas of the body. The clinical features of Chromoblastomycosis, including its chronic, indolent progression, help differentiate it from other cutaneous infections. However, clinical diagnosis alone is not definitive and must be confirmed with laboratory methods.⁽¹⁹⁾

Laboratory Diagnosis

Direct Microscopy

The most direct laboratory method for diagnosing Chromoblastomycosis is direct microscopy of tissue samples. Infected tissues such as skin scrapings, punch biopsies, or exudates from the lesion are examined under a microscope after being treated with potassium hydroxide (KOH). The presence of muriform (sclerotic) cells, which are darkly pigmented and have a brick-like appearance, is characteristic of Chromoblastomycosis. These cells are multinucleated and represent the fungal yeast form. In some cases, fungal hyphae may also be visible, though the hallmark is the presence of the sclerotic bodies.

Histopathology

Histopathological examination is an essential step in confirming the diagnosis. Tissue sections are stained using various methods, including Hematoxylin and Eosin (H&E) and Periodic Acid-Schiff (PAS) stain. The H&E stain allows for the identification of granulomatous inflammation surrounding the fungal cells, while the PAS stain specifically highlights the fungal cell wall structures. In Chromoblastomycosis, the characteristic muriform cells with their pigmented walls can be easily identified, and the granulomatous reaction helps distinguish the disease from other conditions.

Culture

Isolation of the causative fungal species is typically performed on Sabouraud's dextrose agar supplemented with antibiotics to prevent bacterial contamination. The fungi grow as dematiaceous moulds, and the colony morphology varies depending on the species. *Fonsecaea pedrosoi*, one of the most common pathogens, forms black, velvety colonies with a white or greyish appearance at first, transitioning to dark brown or black with age. Growth is typically slow, and identification of the fungus is based on morphological features, such as conidia and hyphal structure.

Molecular Diagnostics

PCR-Based Techniques

Molecular methods such as polymerase chain reaction (PCR) have emerged as rapid, accurate, and specific tools for diagnosing Chromoblastomycosis. PCR assays can detect fungal DNA from tissue samples, which allows for the identification of the causative species. This method has high sensitivity and specificity compared to conventional culture techniques, especially in cases with low fungal burden or when culture results are negative. PCR-based techniques have also been shown to differentiate between different dematiaceous fungi causing Chromoblastomycosis, making it a valuable tool for species-level identification.

DNA Sequencing Methods

For further confirmation, DNA sequencing can be used to determine the internal transcribed spacer (ITS) regions of fungal ribosomal RNA. Sequencing the ITS region of fungal DNA allows for a highly accurate identification of species and provides a genetic fingerprint for phylogenetic analysis. This technique has been particularly useful in distinguishing between similar-looking species and confirming the diagnosis of rare or

unusual fungal pathogens.

Serological and Immunological Tests

Serological tests for Chromoblastomycosis are still under development, though emerging immunological tests may play a role in diagnosis in the future. Recent studies have evaluated enzyme-linked immunosorbent assays (ELISA) and lateral flow assays for detecting specific antibodies or antigens produced in response to fungal infection. However, these tests are not yet widely used in clinical practice and require further validation to confirm their reliability and sensitivity.

Imaging

While imaging is not routinely used in the diagnosis of Chromoblastomycosis, it can be helpful in assessing deep tissue involvement, particularly in advanced or complicated cases. X-rays and CT scans may show changes in the bone or subcutaneous tissues in cases with secondary infection or extensive disease progression. However, imaging is generally less sensitive than laboratory methods for confirming the fungal infection itself.(20-21)

Advantages and Limitations of Diagnostic Methods

Each diagnostic method has its advantages and limitations:

Direct Microscopy is quick and inexpensive, but it requires expertise in identifying muriform cells and may not detect low fungal loads.

Histopathology provides clear evidence of infection but can be time-consuming and may require special staining techniques.

Culture remains the gold standard for fungal identification but has limitations in terms of the slow growth of the fungus and the possibility of contamination.

PCR-based methods offer high sensitivity and specificity but require specialized equipment and expertise.

Serological tests hold promise for future diagnostics but are not yet fully reliable.

Imaging can help assess complications but does not provide a definitive diagnosis.(22)

RECENT ADVANCES AND CHALLENGES

The field of Chromoblastomycosis diagnosis and treatment has seen significant advances in recent years, yet several challeng-

es remain, particularly in understanding the complex fungal pathogenesis and host immune response. This section will discuss the emerging diagnostic tools, gaps in understanding the disease, and challenges faced in clinical settings, particularly in resource-limited environments. Additionally, the potential role of artificial intelligence (AI) in enhancing dermatological diagnosis will be explored.

Emerging Diagnostic Tools

Recent advancements in diagnostic techniques have improved the ability to detect and identify Chromoblastomycosis more rapidly and accurately. One of the most promising developments is the use of next-generation sequencing (NGS). This technology allows for the sequencing of entire fungal genomes, providing a high-resolution approach to species identification. NGS has been shown to improve diagnostic accuracy and facilitate phylogenetic analysis, enabling researchers and clinicians to identify rare and previously uncharacterized fungal pathogens in cases of Chromoblastomycosis. Additionally, NGS has the potential to detect fungal DNA in cases with low fungal burden, where traditional culture and microscopy methods might fail.(23-24)

Another innovative diagnostic tool gaining attention is Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS). MALDI-TOF MS has emerged as a fast and efficient method for identifying fungal species in clinical microbiology. This technique works by analyzing the protein profiles of pathogens, providing a rapid species identification. Studies have demonstrated that MALDI-TOF MS is effective for identifying dematiaceous fungi such as *Fonsecaea pedrosoi* and *Cladophialophora carrionii*, which are commonly associated with Chromoblastomycosis. It is expected that this method will reduce diagnostic time, particularly in hospitals where rapid results are essential for appropriate treatment.

Gaps in Understanding Fungal Pathogenesis and Host Immune Response

Despite advancements in diagnostic techniques, significant gaps remain in our understanding of the pathogenesis of Chromoblastomycosis. One of the key challenges is understanding how the fungi survive and proliferate in the human host. Studies have shown that *Fonsecaea pedrosoi* and other causative agents are capable of adapting to the host immune system by

utilizing various virulence factors, including melanin production. Melanin plays a crucial role in fungal protection against oxidative stress and immune evasion, but the precise mechanisms through which it aids in disease progression are still under investigation. Additionally, the host immune response, particularly the interplay between the innate and adaptive immune systems, remains incompletely understood. The granulomatous inflammation observed in affected tissues suggests a complex interaction between the fungi and the host immune system, which may influence disease severity and progression.

One area where further research is needed is in identifying the specific immune markers associated with Chromoblastomycosis. Understanding the immune evasion strategies employed by the fungi could aid in the development of targeted therapies and help elucidate why some individuals are more susceptible to infection than others, particularly in the context of immune-compromised states.

Challenges in Timely and Accurate Diagnosis in Resource-Limited Settings

Despite these advances, diagnosis in resource-limited settings remains a major challenge. Traditional diagnostic methods, such as direct microscopy and histopathology, are still the mainstay in many regions, especially in developing countries. These methods, although useful, require significant expertise and access to specialized equipment that may not be available in rural or under-resourced areas. Moreover, culture-based methods require prolonged incubation periods, which may delay diagnosis and treatment, particularly in severe cases where prompt intervention is necessary.(25-26)

The high cost and limited availability of advanced diagnostic techniques like NGS and MALDI-TOF MS further exacerbate these challenges in low-resource settings. While these methods offer significant advantages in terms of accuracy and speed, their adoption is hindered by financial constraints and a lack of specialized infrastructure. This underscores the need for low-cost, rapid diagnostic tools that can be implemented in resource-limited environments without compromising accuracy.

The Role of Artificial Intelligence in Dermatological Diagnosis

Artificial intelligence (AI) has the potential to revolutionize dermatological diagnosis, including the identification of Chromoblastomycosis. AI-based systems, particularly those employing deep learning algorithms, can analyze dermatological images and clinical data to assist in the diagnosis of skin diseases. By training AI models on large datasets of dermatological images, these systems can identify patterns associated with Chromoblastomycosis and other skin infections more efficiently than human dermatologists.

Recent studies have shown that AI-powered tools can assist in image recognition, distinguishing between fungal infections and other dermatological conditions. For instance, an AI model trained on images of fungal lesions could help clinicians differentiate Chromoblastomycosis from other diseases like sporotrichosis or mycetoma, which have similar presentations. AI could also be integrated with diagnostic imaging tools, such as dermoscopes and skin scanners, to improve the detection of early-stage lesions.(27)

However, while AI holds promise, it is important to acknowledge that it is not a replacement for human expertise but rather a complementary tool that can aid in decision-making. The integration of AI into clinical practice will require careful validation and regulatory approval to ensure its safety and effectiveness.

FUTURE DIRECTIONS

Despite the progress in understanding Chromoblastomycosis, significant gaps remain in comprehending its pathogenesis, improving diagnostic methods, and developing more effective treatment options. The following are some of the key areas for future research and advancement in the management of this disease.

Areas for Further Research in Understanding Pathogenesis

Research into the pathogenesis of Chromoblastomycosis is essential for improving treatment strategies. Immune evasion mechanisms employed by dematiaceous fungi need to be explored further, particularly focusing on melanin production and its role in protecting the fungi against host immune responses. Additionally, research into the host-pathogen interaction could lead to new insights into why some individuals are more susceptible to infection, especially in those with immune deficiencies. A better understanding of how fungal spores interact with the skin and the underlying immune system could help in de-

veloping preventive strategies and targeted therapies.(28)

Development of Novel Diagnostic Tools

The need for faster, more affordable, and highly accurate diagnostic tools is paramount in improving the management of Chromoblastomycosis. While next-generation sequencing and MALDI-TOF MS are promising, these technologies are still not widely accessible due to cost and infrastructure limitations in many parts of the world. There is a pressing need for the development of point-of-care diagnostic tools, such as lateral flow immunoassays or rapid PCR tests, that could be used in resource-limited settings to provide quick and accurate diagnoses. In addition, improving the sensitivity and specificity of serological tests would enable early detection, especially in patients with low fungal burden.

Need for Global Surveillance and Reporting Systems

A global surveillance system for Chromoblastomycosis would be invaluable in tracking the prevalence and distribution of the disease, particularly in endemic regions. Current surveillance data are sparse, and there is a need for standardized reporting systems that could help monitor disease trends and guide public health interventions. Such systems would also facilitate epidemiological studies, allowing for a better understanding of the environmental, occupational, and social factors that contribute to the spread of Chromoblastomycosis.(29)

CONCLUSION

In conclusion, Chromoblastomycosis remains a significant challenge for clinicians due to its chronic nature, complex pathogenesis, and diagnostic difficulties. The disease's global distribution, particularly in tropical and subtropical regions, underscores the importance of early diagnosis and an in-depth understanding of the mechanisms driving its progression. This review highlights the critical need for continued research into the immune response, fungal pathogenesis, and diagnostic advancements. The combination of traditional diagnostic methods with emerging technologies, such as NGS and MALDI-TOF MS, has the potential to revolutionize the way Chromoblastomycosis is detected and treated. Moreover, interdisciplinary collaboration between clinicians, microbiologists, immunologists, and public health experts is essential to enhance patient outcomes. A comprehensive approach, combining effective diagnosis, timely treatment, and preventive strategies, will be key to reducing the burden of this disease. Through the

development of novel tools and global collaboration, the management of Chromoblastomycosis can be significantly improved, benefiting patients worldwide.

REFERENCES

1. Queiroz-Telles F, de Hoog S, Santos DWCL, Salgado CG, Vicente VA, Bonifaz A, et al. Chromoblastomycosis. *Clin Microbiol Rev.* 2017;30(1):233–76.
2. Savioli L, Crompton DWT, Daumerie D. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected tropical diseases. Vol. 2. World Health Organization; 2013.
3. Jabir M, Choolayil AC. Neglected Tropical Diseases: A Brief Introduction to the Global Scenario. In: *Social Work with Populations Vulnerable to Neglected Tropical Diseases: Evidence and Insights from India.* Springer; 2024. p. 1–17.
4. Organization WH. Control of Neglected Tropical Diseases: Chromoblastomycosis and Other Deep Mycoses. 2017.
5. Santos DWCL, de Azevedo C de MP e S, Vicente VA, Queiroz-Telles F, Rodrigues AM, de Hoog GS, et al. The global burden of chromoblastomycosis. *PLoS Negl Trop Dis.* 2021;15(8):e0009611.
6. Belda Jr W, Casolato ATS, Luppi JB, Passero LFD. Managing chromoblastomycosis with acitretin plus imiquimod: a case report on the improvement of cutaneous lesions and reduction of the treatment time. *J Dermatol.* 2021;48(10):1612–5.
7. Martínez RL, Tovar LJM. Chromoblastomycosis. *Clin Dermatol.* 2007;25(2):188–94.
8. Passero LFD, Cavallone IN, Belda Jr W. Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis. *J Immunol Res.* 2021;2021(1):9742832.
9. Brito AC de, Bittencourt M de JS. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update. *An Bras Dermatol.* 2018;93:495–506.
10. Santos DWCL, Vicente VA, Weiss VA, de Hoog GS, Gomes RR, Batista EMM, et al. Chromoblastomycosis in an endemic area of Brazil: a clinical-epidemiological analysis and a worldwide haplotype network. *J Fungi.* 2020;6(4):204.
11. Hay R, Denning DW, Bonifaz A, Queiroz-Telles F, Beer K, Bustamante B, et al. The diagnosis of fungal neglected tropical diseases (fungal NTDs) and the role of investigation and laboratory tests: an expert consensus report. *Trop Med Infect Dis.* 2019;4(4):122.
12. Hasanajani Roshan MR, Shafigh E, Amanlo M, Sefidgar AA, Shidfar MR. The first case report of chromoblastomycosis in Mazandaran. *J Maz Univ Med Sci.* 2001;11(30):74–80.
13. Santos ALS, Palmeira VF, Rozental S, Kneipp LF, Nimrichter L, Alviano DS, et al. Biology and pathogenesis of *Fonsecaea pedrosoi*, the major etiologic agent of chromoblastomycosis. *FEMS Microbiol Rev.* 2007;31(5):570–91.
14. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. *Med Mycol.* 2009;47(1):3–15.
15. Ezemba Chinyere C, Anyaogu Ebuka V, Etikudike Victor O, Osuala Oluchi J, Ezemba AS, Madukwe Chiamaka J. Pathogenesis and Immunology of Chromoblastomycosis: A review. *J Adv Microbiol Res.* 2020;1(2):61–6.
16. Queiróz AJR, Pereira Domingos F, Antônio JR. Chromoblastomycosis: clinical experience and review of literature. *Int J Dermatol.* 2018;57(11):1351–5.
17. Lu S, Lu C, Zhang J, Hu Y, Li X, Xi L. Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics. *Mycopathologia.* 2013;175:489–95.
18. Damayanti N, Noor L, Purwanto H, Siswati A. Diagnosis and therapy of chromoblastomycosis. *J Pakistan Assoc Dermatologists.* 2022;32(2):443–8.
19. Minotto R, Bernardi CDV, Mallmann LF, Edelweiss MIA, Scroferneker ML. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. *J Am Acad Dermatol.* 2001;44(4):585–92.
20. Silva JP, de Souza W, Rozental S. Chromoblastomycosis: a retrospective study of 325 cases on Amazonian

- Region (Brazil). *Mycopathologia*. 1998;143:171–5.
21. Maubon D, Garnaud C, Ramarozatovo LS, Fahafahantsoa RR, Cornet M, Rasamoelina T. Molecular diagnosis of two major implantation mycoses: chromoblastomycosis and sporotrichosis. *J Fungi*. 2022;8(4):382.
 22. Zaias N, Rebell G. A simple and accurate diagnostic method in chromoblastomycosis. *Arch Dermatol*. 1973;108(4):545–6.
 23. Queiroz-Telles F, de CL Santos DW. Challenges in the therapy of chromoblastomycosis. *Mycopathologia*. 2013;175:477–88.
 24. Breda LCD, Menezes IG, Paulo LNM, de Almeida SR. Immune sensing and potential immunotherapeutic approaches to control chromoblastomycosis. *J Fungi*. 2020;7(1):3.
 25. Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. *Curr Opin Infect Dis*. 2006;19(2):148–52.
 26. Walsh TJ. Invasive fungal infections: problems and challenges for developing new antifungal compounds. In: *Emerging Targets in Antibacterial and Antifungal Chemotherapy*. Springer; 1992. p. 349–73.
 27. Sousa GSM, De Oliveira RS, De Souza AB, Monteiro RC, Santo EPTE, Franco Filho LC, et al. Identification of Chromoblastomycosis and Phaeohyphomycosis Agents through ITS-RFLP. *J Fungi*. 2024;10(2):159.
 28. Hoffmann C de C, Danucalov IP, Purim KSM, Queiroz-Telles F. Infections caused by dematiaceous fungi and their anatomoclinical correlations. *An Bras Dermatol*. 2011;86:138–41.
 29. Moehling TJ, Choi G, Dugan LC, Salit M, Meagher RJ. LAMP diagnostics at the point-of-care: emerging trends and perspectives for the developer community. *Expert Rev Mol Diagn*. 2021;21(1):43–61.